T cell costimulatory blockade: New therapies for transplant rejection

Journal of the American Society of Nephrology

Volumn 10, Issue 6, 1999, Pages 1356-1365

  Gudmundsdottir, Hrefna ^a   Turka, Laurence A ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR;

CELL PROLIFERATION; CELL STIMULATION; CELL SURFACE; CELL SURVIVAL; CLONAL ANERGY; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; GRAFT REJECTION; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0032997619     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (72)

1. Gjertson D: Survival trends in long-term first cadaver-donor kidney transplants. In: Clinical Transplants, edited by Terasaki P, Los Angeles, UCLA Tissue Typing Laboratory, 1991, pp 225-235
2. Tilney N, Paul L: Antigen-independent events leading to chronic graft dysfunction. In: Transplantation Biology, 1st Ed., edited by Tilney N, Strom T, Paul L, Philadelphia, Lippincott-Raven, 1996, pp 629-637
3. Paul L, Tilney N: Alloantigen-dependent events in chronic rejection. In: Transplantation Biology, 1st Ed., edited by Tilney N, Strom T, Paul L, Philadelphia, Lippincott-Raven, 1996, pp 567-575
4. Janeway CA Jr, Bottomly K: Signals and signs for lymphocyte responses. Cell 76: 275-285, 1994
5. Van Parijs L, Abbas AK: Homeostasis and self-tolerance in the immune system: Turning lymphocytes off. Science (Washington DC) 280: 243-248, 1998
6. Khoruts A, Jenkins MK: Studying immunological tolerance by physically monitoring antigen-specific T cells in vivo. Ann NY Acad Sci 778: 72-79, 1996
7. Qin S, Cobbold S, Pope H, Elliott J, Kioussis D, Davies J, Waldmann H: "Infectious" transplantation tolerance. Science (Washington DC) 259: 974-976, 1993
8. Lombardi G, Sidhu S, Batchelor R, Lechler R: Anergic T cells as suppressor T cells in vitro. Science (Washington DC) 264: 1587-1589, 1994
9. Sayegh MH, Turka LA: The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 338: 1813-1821, 1998
10. Sayegh MH, Watschinger B, Carpenter CB: Mechanisms of T cell recognition of alloantigen: The role of peptides. Transplantation 57: 1295-1302, 1994
11. Lechler RI, Lombardi G, Batchelor JR, Reinsmoen N, Bach FH: The molecular basis of alloreactivity. Immunol Today 11: 83-88, 1990
12. Ciubotariu R, Liu Z, Colovai AI, Ho E, Itescu S, Ravalli S, Hardy MA, Cortesini R, Rose EA, Suciu-Foca N: Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest 101: 398-405, 1998
13. Berke G: The function and mechanism of action of cytolytic lymphocytes. In: Fundamental Immunology, 3rd Ed., edited by Paul WE, New York, Raven, 1993, pp 965-974
14. Mondino A, Khoruts A, Jenkins MK: The anatomy of T-cell activation and tolerance. Proc Natl Acad Sci USA 93: 2245-2252, 1996
15. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP: CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature (Lond) 356: 607-609, 1992
16. Jenkins MK, Schwartz RH: Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 165: 302-319, 1987
17. Lenschow DJ, Walunas TL, Bluestone JA: CD28/B7 system of T cell costimulation. Annu Rev Immunol 14: 233-258, 1996
18. Reiser H, Stadecker MJ: Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med 335: 1369-1377, 1996
19. Rudd CE: Upstream-downstream: CD28 cosignaling pathways and T cell function. Immunity 4: 527-534, 1996
20. Judge TA, Tang A, Spain LM, Deans-Gratiot J, Sayegh MH, Turka LA: The in vivo mechanism of action of CTLA4Ig. J Immunol 156: 2294-2299, 1996
21. Boussiotis VA, Freeman GJ, Gray G, Gribben J, Nadler LM: B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance. J Exp Med 178: 1753-1763, 1993
22. Gimmi CD, Freeman GJ, Gribben JG, Gray G, Nadler LM: Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA 90: 6586-6590, 1993
23. Radvanyi LG, Shi Y, Vaziri H, Sharma A, Dhala R, Mills GB, Miller RG: CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response. J Immunol 156: 1788-1798, 1996
24. Boise LH, Minn AJ, Noel PJ, June CH, Accavitti MA, Lindsten T, Thompson CB: CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 3: 87-98, 1995
25. Van Parijs L, Ibraghimov A, Abbas AK: The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance. Immunity 4: 321-328, 1996
26. Van Parijs L, Biuckians A, Abbas AK: Functional roles of Fas and Bcl-2-regulated apoptosis of T lymphocytes. J Immunol 160: 2065-2071, 1998
27. Nagata S, Golstein P: The Fas death factor. Science (Washington DC) 267: 1449-1456, 1995
28. Mor F, Cohen IR: IL-2 rescues antigen-specific T cells from radiation or dexamethasone-induced apoptosis: Correlation with induction of Bcl-2. J Immunol 156: 515-522, 1996
29. Refaeli Y, Van Parijs L, London CA, Tschopp J, Abbas AK: Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 8: 615-623, 1998
30. Suzuki H, Kundig TM, Furlonger C, Wakeham A. Timms E, Matsuyama T, Schmits R, Simard JJ, Ohashi PS, Griesser H: Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor β. Science (Washington DC) 268: 1472-1476, 1995
31. Krummel MF, Allison JP: CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 183: 2533-2540, 1996
32. Walunas TL, Bakker CY, Bluestone JA: CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 183: 2541-2550, 1996
33. Perez V, Parijs LV, Biuckians A, Zheng X, Strom T, Abbas A: Induction of peripheral T cell tolerance in vivo required CTLA-4 engagement. Immunity 6: 411-417, 1997
34. Gribben JG, Freeman GJ, Boussiotis VA, Rennert P, Jellis CL, Greenfield E, Barber M, Restivo VA, Ke X, Gray GS, Nadler LM: CTLA4 mediates antigen-specific apoptosis of human T cells. Proc Natl Acad Sci USA 92: 811-815, 1995
35. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW: Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science (Washington DC) 270: 985-988, 1995
36. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3: 541-547, 1995
37. + T cells. Immunity 7: 885-895, 1997
38. Wu Y, Guo Y, Huang A, Zheng P, Liu Y: CTLA-4-B7 interaction is sufficient to costimulate T cell clonal expansion. J Exp Med 185: 1327-1335, 1997
39. Madrenas J, Schwartz RH, Germain RN: Interleukin 2 production, not the pattern of early T-cell antigen receptor-dependent tyrosine phosphorylation, controls anergy induction by both agonists and partial agonists. Proc Natl Acad Sci USA 93: 9736-9741, 1996
40. Allison J: T-cell mediated immunity. In: Immunobiology: The Immune System in Health and Disease, 3rd Ed., edited by Janeway CA Jr, Travers P, Singapore, Stamford Press, 1997, pp 7.15-7.31
41. Truitt KE, Shi J, Gibson S, Segal LG, Mills GB, Imboden JB: CD28 delivers costimulatory signals independently of its association with phosphatidylinositol 3-kinase. J Immunol 155: 4702-4710, 1995
42. Su B, Jacinto E, Hibi M, Kallunki T, Karin M, Ben-Neriah Y: JNK is involved in signal integration during costimulation of T lymphocytes. Cell 77: 727-736, 1994
43. Mondino A, Jenkins MK: Surface proteins involved in T cell costimulation. J Leukocyte Biol 55: 805-815, 1994
44. 2-terminal kinase pathway. Science (Washington DC) 280: 1945-1949, 1998
45. + T cells. Science (Washington DC) 271: 1272-1276, 1996
46. 1 T cells. Science (Washington DC) 271: 1276-1278, 1996
47. Boussiotis VA, Barber DL, Lee BJ, Gribben JG, Freeman GJ, Nadler LM: Differential association of protein tyrosine kinases with the T cell receptor is linked to the induction of anergy and its prevention by B7 family-mediated costimulation. J Exp Med 184: 365-376, 1996
48. Williams TM, Moolten D, Burlein J, Romano J, Bhaerman R, Godillot A, Mellon M, Rauscher FJ, Kant JA: Identification of a zinc finger protein that inhibits IL-2 gene expression. Science (Washington DC) 254: 1791-1794, 1991
49. Yasui DH, Genetta T, Kadesch T, Williams TM, Swain SL, Tsui LV, Huber BT: Transcriptional repression of the IL-2 gene in Th cells by ZEB. J Immunol 160: 4433-4440, 1998
50. Becker JC, Brabletz T, Kirchner T, Conrad CT, Brocker EB, Reisfeld RA: Negative transcriptional regulation in anergic T cells. Proc Natl Acad Sci USA 92: 2375-2378, 1995
51. Kitagawa-Sakakida S, Schwartz RH: Multiple cis-dominant negative regulation of IL-2 gene expression in anergized T cells. J Immunol 157: 2328-2339, 1996
52. Grewal IS, Flavell RA: CD40 and CD 154 in cell-mediated immunity. Annu Rev Immunol 16: 111-135, 1998
53. Yang Y, Wilson JM: CD40 ligand-dependent T cell activation: Requirement of B7-CD28 signaling through CD40. Science (Washington DC) 273: 1862-1864, 1996
54. Shinde S, Wu Y, Guo Y, Niu Q, Xu J, Grewal IS, Flavell R, Liu Y: CD40L is important for induction of, but not response to, costimulatory activity: ICAM-1 as the second costimulatory molecule rapidly up-regulated by CD40L. J Immunol 157: 2764-2768, 1996
55. Pollok KE, Kim YJ, Zhou Z, Hurtado J, Kim KK, Pickard RT, Kwon BS: Inducible T cell antigen 4-1BB: Analysis of expression and function. J Immunol 150: 771-781, 1993
56. Goodwin RG, Din WS, Davis-Smith T, Anderson DM, Gimpel SD, Sato TA, Maliszewski CR, Brannan CI, Copeland NG, Jenkins NA: Molecular cloning of a ligand for the inducible T cell gene 4-1BB: A member of an emerging family of cytokines with homology to tumor necrosis factor. Eur J Immunol 23: 2631-2641, 1993
57. - T lymphocytes by 4-1BB ligand. J Immunol 158: 551-559, 1997
58. Wu Y, Shou Q, Zheng P, Liu Y: CD28-independent induction of T helper cells and immunoglobulin class switches requires costimulation by the heat-stable antigen. J Exp Med 187: 1151-1156, 1998
59. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA: CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174: 561-569, 1991
60. Sayegh MH, Turka LA: T cell costimulatory pathways: Promising novel targets for immunosuppression and tolerance induction. J Am Soc Nephrol 6: 1143-1150, 1995
61. Harlan DM, Kirk AD: Anti-CD 154 therapy to prevent graft rejection. Graft 1: 63-70, 1998
62. Sayegh M, Zheng X-G, Magee C, Hancock W, Turka L: Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allografts. Transplantation 64: 1646-1650, 1997
63. Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, Tucker-Burden C, Cho HR, Aruffo A, Hollenbaugh D, Linsley PS, Winn KJ, Pearson TC: Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature (Lond) 381: 434-438, 1996
64. Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, Hong X, Thomas D, Fechner JH Jr, Knechtle SJ: CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 94: 8789-8794, 1997
65. Levisetti M, Padrid P, Szot G, Mittal N, Meehan S, Wardrip C, Gray G, Bruce D, Thistlethwaite J, Bluestone J: Immunosuppressive effects of hCTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol 159: 5187-5191, 1997
66. Chang AC, Blum MG, Scott M, Thomas DW, Pierson RN: Antibody to CD40 ligand prolongs primate cardiac allograft survival [Abstract]. In: Proceedings of the 23rd American Society of Transplant Surgeons Annual Meeting, Thorofare, NJ, American Society of Transplant Surgeons, 1997
67. Judge TA, Wu Z, Zheng X-G, Sharpe AH, Sayegh MH, Turka LA: The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. J Immunol 162: 1947-1951, 1999
68. Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA: CTLA-4, a negative regulator of autoimmune disease. J Exp Med 184: 783-788, 1996
69. Luhder F, Hoglund P, Allison JP, Benoist C, Mathis D: Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med 187: 427-432, 1998
70. Hurwitz AA, Sullivan TJ, Krummel MF, Sobel RA, Allison JA: Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively induced model of experimental allergic encephalomyelitis. J Neuroimmunol 73: 57-62, 1997
71. Azuma H, Chandraker A, Nadeau K, Hancock WW, Carpenter CB, Tilney NL, Sayegh MH: Blockade of T cell costimulation prevents development of experimental chronic allograft rejection. Proc Natl Acad Sci USA 93: 12439-12444, 1996
72. Takada M, Chandraker A, Nadeau KC, Sayegh MH, Tilney NL: The role of the B7 costimulatory pathway in experimental cold ischemia/reperfusion injury. J Clin Invest 100: 1199-1203, 1997